 The Pharmaceutical Care Management Association, the main industry group for PBMs, strongly disputed the FTC's report, pointing out anonymous sourcing and what the group referred to as cherry-picked case studies. Some current and former FTC officials concurred, along with some in academia. I do not believe the report has evidence showing PBMs harmed patients and plant sponsors.